Bio-Rad Adds Digital PCR
Brad Crutchfield, vice president of Bio-Rad Laboratories Life Science Group, told IBO “ddPCR systems have begun to ship and, by early in 2012, will be widely available across Bio-Rad’s global sales network.” The systems are currently available in North America.
Hercules, CA 10/5/11—Bio-Rad Laboratories has acquired QuantaLife for $162 million in cash and potential future milestone payments. QuantaLife is a developer of digital PCR technology (see IBO 12/15/10), which can be used for the detection of rare mutations. The company’s Droplet Digital system (ddPCR) is used for the validation of next-generation sequencing results. “We are impressed with QuantaLife’s digital PCR technology and believe it will complement Bio-Rad’s existing amplification business,” said Bio-Rad President and CEO Norman Schwartz.
